Drug intelligence / Profile preview

RNAi-based treatment for geographic atrophy

Development stage: Preclinical
Lead developer: City Therapeutics
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravitreal

Overview

A novel RNAi-based therapeutic approach being developed through a strategic collaboration between City Therapeutics and Bausch + Lomb for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). This therapy utilizes RNA interference technology to potentially address the underlying mechanisms of GA progression, offering a different approach from the complement inhibition mechanism used by currently approved treatments.

Beyond the preview

Go deeper on RNAi-based treatment for geographic atrophy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNAi-based treatment for geographic atrophy.

Explore the full profile